These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32753406)

  • 1. Tailoring B cell depletion therapy in MS according to memory B cell monitoring.
    Novi G; Bovis F; Fabbri S; Tazza F; Gazzola P; Maietta I; Currò D; Bruschi N; Roccatagliata L; Boffa G; Lapucci C; Pesce G; Cellerino M; Solaro C; Laroni A; Capello E; Mancardi G; Sormani M; Inglese M; Uccelli A
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32753406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
    Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
    Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.
    Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33087582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
    Claverie R; Perriguey M; Rico A; Boutiere C; Demortiere S; Durozard P; Hilezian F; Dubrou C; Vely F; Pelletier J; Audoin B; Maarouf A
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37604695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
    Juto A; Fink K; Al Nimer F; Piehl F
    Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
    Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
    Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Obinutuzumab in Children With Autoimmune Encephalitis and Early B-Cell Repopulation on Rituximab.
    Nguyen AT; Cotteret C; Gins C; Sarda E; Durrleman C; Mesples B; Bustamante J; Fayard C; Cisternino S; Desguerre I; Aubart M
    Pediatr Neurol; 2024 Jul; 156():79-84. PubMed ID: 38733858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
    Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
    Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
    J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
    Delbet JD; Leclerc G; Ulinski T
    Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.
    Meltzer E; Campbell S; Ehrenfeld B; Cruz RA; Steinman L; Parsons MS; Zamvil SS; Frohman EM; Frohman TC
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32769201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.